It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery’s Chemical Stability assay provides a comprehensive in vitro evaluation of compound degradation across a wide range of physiological and biorelevant media. Chemical stability is essential for predicting the behaviour of orally administered molecules, particularly during transit through the gastrointestinal tract where pH, buffer composition and food effects can significantly influence degradation rates. The assay evaluates non‑enzymatic degradation pathways, including hydrolysis, oxidation and other chemical transformations that may occur under different pH and environmental conditions.
The validation assessed stability in phosphate‑buffered saline (PBS), biorelevant gastric and intestinal fluids (FaSSGF, FeSSIF, FaSSIF), fed‑state gastric media (FEDGAS) and USP‑defined buffers. Test compounds were incubated in the relevant media, and compound disappearance monitored over time using LC–MS/MS. Percent remaining and half‑life values were calculated from depletion kinetics, providing a robust measure of stability across media.
By incorporating a range of physiological and biorelevant media, the platform enables assessment of compound stability under fasted, fed, gastric, and intestinal conditions, while also supporting evaluation in formulation‑relevant environments. Overall, the dataset confirms that the chemical stability platform is an essential early‑stage DMPK tool for identifying compounds with suitable stability profiles to progress within oral drug‑development programmes.
Protocol Summary
The chemical stability assay evaluates the degradation profile of compounds across multiple physiologically relevant media to determine their intrinsic degradation rates. Test compounds are first prepared from concentrated DMSO stock solutions, then incubated in the selected buffer or biorelevant medium. At predetermined time points, aliquots are removed and quenched immediately using organic solvent to prevent further degradation, generating a time course of compound disappearance.
Following centrifugation to remove precipitated proteins, supernatants are pooled for cassette analysis (except if screening for prodrugs) and diluted with water containing internal standard. Samples are analysed via LC–MS/MS to determine the percentage parent compound remaining at each time point. Natural log transformation of compound response–time data enables linear regression to derive the elimination rate constant (k), from which half‑life values are calculated, thus providing a quantitative measure of stability.
This workflow supports high reproducibility by using consistent incubation formats, sampling schedules and analytical conditions. Overall, the assay enables efficient, accurate and physiologically relevant stability assessment for a broad range of drug candidates intended for oral administration.
Validation Results
Validation across all matrices demonstrated strong reproducibility and robust performance, enabling detailed stability characterisation across diverse pH conditions. Across buffer and biorelevant media, the assay showed acceptable reproducibility, with variability maintained below 20% CV.
The graph below presents the validated inter‑assay data for 0.1M PBS (pH 7.4):